PhRMA Commitment to Equity

Edit Background Image

Diversity is critical to the work we do.

Systematic racism is as real as any disease for which we work toward a cure. Our bio pharmaceutical companies pioneer change and drive the future of progress for patients. We’re committed to driving real change toward racial equality and inclusion for better patient, industry and healthcare outcomes.

Edit Background Image

PhRMA Statement on Presidential Executive Order Restricting Diversity Training

“The biopharmaceutical industry is doing everything it can to find vaccines and therapeutics to help end a pandemic that has had a disproportionate impact on Black and Brown communities.”

Edit Background Image

Addressing health inequities: Biopharmaceutical companies are rising to the occasion

By Freda Lewis-Hall, MD, DFAPA, MFPM
The Washington Post, October 12

“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.

I urge you to follow the progress at PhRMA.org/Equity.”

READ THE ARTICLE

PhRMA Blog Articles on Diversity, Equity, and Inclusion (DE&I)

3 Reasons Innovation Depends On Strong IP Protections in the TPP

by Ali Unknown

Equity Form Placeholder

PhRMA Commitment to Diversity, Equity, and Inclusion Print Ad

WASHINGTON, D.C. (July 28, 2020)

Diversity is essential to a robust innovation ecosystem that can create new medicines for those who need them. America’s biopharmaceutical companies are pushing for necessary, positive and long-term change to better meet the needs of Black and Brown America.

That means:

Open, honest, real conversations about racial equity and what it means to have a culture of inclusion.
Expanding opportunities to work and succeed in our industry.
Advancing policy solutions and research to better address health disparities.
Diversifying our business practices to better invest in Black and Brown America.
Earning trust and addressing systemic issues that deter Black and Brown communities from participating in clinical trials, so that people who want to participate, can.

DOWNLOAD PRINT AD